Table 2.
Exposure and dose modifications
| Parameter | Ramucirumab, n = 23 | Merestinib, n = 23 |
|---|---|---|
| Exposure, median (range) | ||
| Duration of therapy, wk | 10.0 (2.0–60.7) | 12.0 (4.0–60.7) |
| Number of cycles | 3.0 (1.0–15.0) | 3.0 (1.0–15.0) |
| Relative dose intensity, % | 99.4 (73.6–103.1) | 84.8 (50.0–100.0) |
| Dose modifications | ||
| Dose reduction, n (%) | 1 (4.3) | 2 (8.7) |
| Dose delay, n (%) | 12 (52.2) | NA |
| Dose omission, n (%) | 4 (17.4) | 14 (60.9) |
| Dose omission length, a % | 9.4 | 10.3 |
a
Percentage of dose holding time with respect to total time on treatment.
Abbreviation: NA, not applicable.